Inclusion Criteria:

1. Patients with colorectal cancer meeting one of the following criteria: 1. naive to
oxaliplatin or to any microtubule stabilizing agents (e.g. Taxol, Abraxane,
Ixabepilone) but scheduled for combined oxaliplatine chemotherapy (longitudinal study
cohort 1); or 2. during first 5 years from colorectal cancer diagnosis
(cross-sectional study cohort). This second cohort may include patients with
colorectal cancer from the original 12-month study (the longitudinal cohort), both
those who completed the study and those who dropped out. It may also include new
patients who did not participate in the longitudinal phase of the study.

2. Patients >= 18 years old.

3. Patients who speak English or Spanish.

Exclusion Criteria:

1. Cohort 1 patients with a neuropathy score of 1 or greater on the NCI's Common
Terminology Criteria (CTCv3.0).

2. Patients who do not understand the intent of the study.

3. Cohort 1 patients unable to use the interactive voice response (IVR) system due to
physical limitations (e.g., hearing impairment).

4. Cohort 1 patients with a history of inflammatory bowel disease.